Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® ...

The UnitedHealth Group division is taking Johnson & Johnson's Stelara — one of the most popular, best-known and most expensive "biologic" anti-inflammatory drugs — off the standard formulary for many ...

BMY depends on label expansion of approved drugs and approval of new drugs to stabilize its revenue base as its legacy drugs ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15%, is indicated ...

AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is ...

Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health ...

Bristol MyersBMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis ...

Products containing CBD are growing in popularity and availability. As part of our “Ask the Expert” series, in partnership ...

It’s no secret Coloradans are struggling to afford the cost of living today. From eggs to cars to housing, raising prices are ...

Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

South Korea’s biosimilar drug developer Samsung Bioepis has announced that the company has entered into a license, ...